News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chimerix, Inc. and Biomedical Advanced Research and Development Authority (BARDA) Continue Collaboration on Development of CMX001 as a Medical Countermeasure Against Smallpox



6/3/2013 10:27:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DURHAM, N.C., June 3, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the continued development of CMX001 as a potential medical countermeasure against smallpox, which is classified as a Category A bioterror agent by the U.S. Centers for Disease Control and Prevention. The extension of the contract provides $5 million in funding over 12 months for Chimerix to conduct animal studies that are necessary for an approval of CMX001 for treatment of smallpox infection under the U.S. Food and Drug Administration's (FDA) Animal Efficacy Rule.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES